Epitome Antiviral Revenue

About Epitome Antiviral

Our mission is focused on the treatment of acute respiratory distress. SARS is another name for the same condition, where the lungs are inflamed and there is a cytokine storm. Inhaled green tea extract gave rapid recovery to 10 COVID-19 patients in a clinical trial; 7/10 were virus-free after a median of 9 days. We seek a partner to take the Green-Tea inhalation therapy through clinical development. A pilot trial in 10 COVID-19 patients succeeded in 2020, see below. We applied for an IND at the FDA and will need sites to test the therapy. Look forward to hearing from you. Our Italian colleagues invented this concept and conducted a pilot clinical trial in 10 swab-positive COVID-19 subjects in Italy during the COVID surge in the fall of 2020. All had symptoms of mild-to-moderate disease; the older 5 subjects had IL-6 levels of geometric mean 74 pg/ml, diagnostic for severe disease. All subjects were cured of symptoms after a median of 9 days of treatment, range 7 - 15. 7/10 had negative swabs for SARS-Cov-2 at that time. Comparing these results to a population study of 4,430 COVID-19 swab positive patients in the next province (Mancuso et al. 2020) gave a probability of P < 0.003. (doi: 10.1136/bmjopen-2020-040380) Our pilot trial will duplicate their course of treatment. The peer-reviewed paper is published here: https://www.mdpi.com/2673-8112/1/1/2/htm The severe form of COVID-19 is called SARS (Severe acute respiratory syndrome). It is virtually the same as ARDS (Acute Respiratory Distress Syndrome) which affects 200,000 patients in the US every year due to pneumonia and other causes. We speculate that COVID-Tea therapy will be effective for ARDS. We need collaborators and partnerships to bring this therapy to commercial success.

View contact profiles from Epitome Antiviral